Joining the exodus at Gilead, CMO Andrew Cheng makes the switch to biotech CEO — triggering a cross-country move for Akero
Andrew Cheng spent close to 20 years at Gilead, ending as its chief medical officer after playing a key role in developing a string of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
